Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 203

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 203
---
) 
    $876,367 
  
    Vesting of restricted stock units  
    $428  
    $- 
  
    Stock issued for investment 
    $150,000  
    $- 
  
    Stock issued for licensing agreement 
    $1,000,000  
    $- 
  
    Accrued expense for licensing agreement 
    $500,000  
    $- 
  
    Warrants issued as debt discount 
    $98,684  
    $- 
  
    Derivative liabilities as debt discount 
    $341,576  
    $- 
  
    Preferred stock subscription 
    $4,400,000  
    $- 

The
accompanying notes are an integral part of these consolidated financial statements.

F-7

PetVivo
Holdings, Inc.

Notes
to Consolidated Financial Statements

March
31, 2025 and 2024

NOTE
1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

(A)
Organization and Description

PetVivo Holdings, Inc. was incorporated in Nevada under a former name in 2009 and entered its current business in
2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming
a wholly-owned subsidiary of PetVivo Holdings, Inc. In April 2017, PetVivo Holdings, Inc. acquired another Minnesota corporation, Gel-Del
Technologies, Inc. through a statutory merger, which is also a wholly-owned subsidiary of PetVivo Holdings, Inc. In April 2025, PetVivo
Holdings, Inc. changed the name of its wholly-owned subsidiary PetVivo, Inc. to PetVivo Animal Health, Inc. to better reflect the industry
in which PetVivo Holdings, Inc. sell our products.

The
Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or
management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product
Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and
other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products
for the treatment of animals in